Related Experiment Video

Updated: Jun 8, 2026

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings
10:46

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

Published on: September 1, 2023

Age and comedications influence levetiracetam pharmacokinetics in children

Maria G Dahlin1, Katarina Wide, Inger Ohman

  • 1Department of Neuropediatrics, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden. maria.dahlin@karolinska.se

Pediatric Neurology
|September 15, 2010
PubMed

Insights

Levetiracetam clearance is higher in younger children and those taking enzyme-inducing medications. Adjusting levetiracetam dosage based on age and comedications is crucial for effective epilepsy treatment in pediatric patients.

Area of Science:

  • Pharmacokinetics
  • Pediatric Epilepsy

Background:

  • Antiepileptic drug pharmacokinetics vary between adults and children.
  • Understanding factors influencing levetiracetam dosing in children is essential.

Purpose of the Study:

  • To investigate the impact of age and concomitant medications on levetiracetam's dose/concentration ratio in pediatric epilepsy patients.
  • To assess levetiracetam's effect on the clearance of other antiepileptic drugs.

Main Methods:

  • Retrospective review of dosing and plasma levels in 103 children with epilepsy.
  • Calculation of dose/concentration ratio as a measure of apparent oral clearance.
  • Classification of children by age groups and concomitant medication types (enzyme inducers, non-enzyme inducers, monotherapy).

Main Results:

  • Levetiracetam clearance was significantly higher in younger children (0-4 years) compared to older groups (5-11 and 12-17 years).
  • Children receiving enzyme-inducing antiepileptic drugs showed significantly higher levetiracetam clearance (1.3-fold) than those on non-enzyme inducers or monotherapy.
  • Levetiracetam did not affect the clearance of lamotrigine, valproate, topiramate, or clonazepam.

Conclusions:

  • Younger age and concurrent use of enzyme-inducing medications increase levetiracetam clearance in children.
  • These pharmacokinetic differences necessitate individualized dosing strategies for levetiracetam in pediatric epilepsy management.

More Related Videos

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...